Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Massimo Morfini & Albert Farrugia. (2019) Pharmacokinetic and safety considerations when switching from standard to extended half-life clotting factor concentrates in hemophilia. Expert Review of Hematology 12:10, pages 883-892.
Read now
Read now
Bernd Tischer, Renato Marino & Mariasanta Napolitano. (2018) Patient preferences in the treatment of hemophilia A: impact of storage conditions on product choice. Patient Preference and Adherence 12, pages 431-441.
Read now
Read now
Changgang Li, Xinsheng Zhang, Yongqiang Zhao, Runhui Wu, Qun Hu, Vicky Xu, Jing Sun, Renchi Yang, Xiaojing Li, Rongfu Zhou, Shinmei Lian, Jian Gu, Junde Wu & Qingsong Hou. (2017) Status and trend analysis of prophylactic usage of recombinant factor VIII in Chinese pediatric patients with hemophilia A: ReCare – a retrospective, phase IV, non-interventional study. Current Medical Research and Opinion 33:9, pages 1571-1578.
Read now
Read now
Articles from other publishers (8)
Irena Preloznik Zupan, Karla Rener & Sasa Anzej Doma. (2022) Treatment satisfaction and limitations in haemophilia A, with a focus on factor VIII product storage conditions: patients’ perspectives and challenges. Drugs & Therapy Perspectives 39:2, pages 71-80.
Crossref
Crossref
Annarita Tagliaferri, Angelo Claudio Molinari, Flora Peyvandi, Antonio Coppola, Francesco Demartis, Chiara Biasoli, Alessandra Borchiellini, Dorina Cultrera, Raimondo De Cristofaro, Filomena Daniele, Paola Giordano, Emanuela Marchesini, Maurizio Margaglione, Renato Marino, Berardino Pollio, Paolo Radossi, Cristina Santoro, Rita Carlotta Santoro, Sergio Siragusa, Gianluca Sottilotta, Alberto Tosetto, Lydia Piscitelli, Maria Rosaria Villa, Ezio Zanon, Adele Finardi, Irene Schiavetti, Daniella Vaccari & Giancarlo Castaman. (2022) IDEAL study: A real‐world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX‐FP) in patients with haemophilia B in Italy. Haemophilia 29:1, pages 135-144.
Crossref
Crossref
Ione Woollacott, George Morgan, Pratima Chowdary, Jamie O'Hara, Bethany Franks, Eline van Overbeeke, Nicola Dunn, Sissel Michelsen, Isabelle Huys, Antony Martin, Matthew Cawson, Jack Brownrigg, Ian Winburn & Jim Thomson. (2022) Examining patient and professional perspectives in the UK for gene therapy in haemophilia. Haemophilia 28:4, pages 588-609.
Crossref
Crossref
Eline van Overbeeke, Brett Hauber, Sissel Michelsen, Michel Goldman, Steven Simoens & Isabelle Huys. (2021) Patient Preferences to Assess Value IN Gene Therapies: Protocol Development for the PAVING Study in Hemophilia. Frontiers in Medicine 8.
Crossref
Crossref
Andrea Aiello, Maria Elisa Mancuso, Alessio Colombo, Cristina Teruzzi & Patrizia Berto. (2020) Budget impact analysis of extended half-life recombinant factor IX (rFIXFc) in the treatment of haemophilia B. Global & Regional Health Technology Assessment 7:1, pages 40-49.
Crossref
Crossref
Erna C. van Balen, Marjolein L. Wesselo, Bridget L. Baker, Marjan J. Westerman, Michiel Coppens, Cees Smit, Mariëtte H. E. Driessens, Frank W. G. Leebeek, Johanna G. van der Bom & Samantha C. Gouw. (2019) Patient Perspectives on Novel Treatments in Haemophilia: A Qualitative Study. The Patient - Patient-Centered Outcomes Research 13:2, pages 201-210.
Crossref
Crossref
Gabriel Pedra, Pia Christoffersen, Kate Khair, Xin Ying Lee, Sonia O’Hara, Jamie O’Hara & John Pasi. (2020) The impact of factor infusion frequency on health-related quality of life in people with haemophilia. The Journal of Haemophilia Practice 7:1, pages 102-109.
Crossref
Crossref
Debra Pollard, Kate Khair, Cléa Percier, Yen Wong & Robyn Shoemark. (2018)
Evaluation of a pre-filled diluent syringe (MixPro
®
) among patient/carer users and nurses
. The Journal of Haemophilia Practice 5:1, pages 12-23.
Crossref
Crossref